RT Journal Article
SR Electronic
T1 The interface between SARS-CoV-2 and non-communicable diseases (NCDs) in a high HIV/TB burden district level hospital setting, Cape Town, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.08.22282097
DO 10.1101/2022.11.08.22282097
A1 Mnguni, Ayanda Trevor
A1 Schietekat, Denzil
A1 Ebrahim, Nabilah
A1 Sonday, Nawhaal
A1 Boliter, Nicholas
A1 Schrueder, Neshaad
A1 Gabriels, Shiraaz
A1 Cois, Annibale
A1 Tamuzi, Jacques L.
A1 Tembo, Yamanya
A1 Davies, Mary-Ann
A1 English, Rene
A1 Nyasulu, Peter S.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/11/10/2022.11.08.22282097.abstract
AB Background COVID-19 experiences on noncommunicable diseases (NCDs) from district-level hospital settings during waves I and II are scarcely documented. The aim of this study is to investigate the NCDs associated with COVID-19 severity and mortality in a district-level hospital with a high HIV/TB burden.Methods This was a retrospective observational study that compared COVID-19 waves I and II at Khayelitsha District Hospital in Cape Town, South Africa. COVID-19 adult patients with a confirmed SARS-CoV-2 polymerase chain reaction (PCR) or positive antigen test were included. In order to compare the inter wave period, clinical and laboratory parameters on hospital admission of noncommunicable diseases, the Student t-test or Mann-Whitney U for continuous data and the X2 test or Fishers’ Exact test for categorical data were used. The role of the NCD subpopulation on COVID-19 mortality was determined using latent class analysis (LCA).Findings Among 560 patients admitted with COVID-19, patients admitted during wave II were significantly older than those admitted during wave I. The most prevalent comorbidity patterns were hypertension (87%), diabetes mellitus (65%), HIV/AIDS (30%), obesity (19%), Chronic Kidney Disease (CKD) (13%), Congestive Cardiac Failure (CCF) (8.8%), Chronic Obstructive Pulmonary Disease (COPD) (3%), cerebrovascular accidents (CVA)/stroke (3%), with similar prevalence in both waves except HIV status [(23% vs 34% waves II and I, respectively), p = 0.022], obesity [(52% vs 2.5%, waves II and I, respectively), p <0.001], previous stroke [(1% vs 4.1%, waves II and I, respectively), p = 0.046]. In terms of clinical and laboratory findings, our study found that wave I patients had higher haemoglobin and HIV viral loads. Wave II, on the other hand, had statistically significant higher chest radiography abnormalities, fraction of inspired oxygen (FiO2), and uraemia. The adjusted odds ratio for death vs discharge between waves I and II was similar (0.94, 95%CI: 0.84-1.05). Wave I had a longer average survival time (8.0 vs 6.1 days) and a shorter average length of stay among patients discharged alive (9.2 vs 10.7 days). LCA revealed that the cardiovascular phenotype had the highest mortality, followed by diabetes and CKD phenotypes. Only Diabetes and hypertension phenotypes had the lowest mortality.Conclusion Even though clinical and laboratory characteristics differed significantly between the two waves, mortality remained constant. According to LCA, the cardiovascular, diabetes, and CKD phenotypes had the highest death probability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committee of Stellenbosch UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the paper and its Supporting Information filesAIDSacquired immunodeficiency syndrome;AKIAcute kidney injury;ARDSAcute respiratory distress syndrome;ACE2Angiotensin-Converting Enzyme 2;ARTantiretroviral therapy;BMIbody mass index;COVID-19:CCFcongestive cardiac failure;Coronavirus disease 2019;Crcreatine;CRPC-Reactive protein;COPDChronic obstructive pulmonary disease;CXRchest x-ray;CVDscardiovascular diseases;DICDisseminated intravascular coagulation;FIO2fraction of inspired oxygen;HAPHospital-acquired; pneumoniaHIVhuman immunodeficiency virus;HGThemo glucose test;ICUintensive care unit;IHDischemic heart disease;IL-6Interleukin-6;IQRinterquartile ranges;JHUJohn Hopkin University;CHDchronic heart disease;CKDchronic kidney diseases;LCALatent Class Analysis;NCDsnon-communicable diseases;RT-PCRreverse transcriptase polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2;SEstandard deviation;SPO2Oxygen saturation;TBtuberculosis;TDFTenofovir disoproxil fumarate;TNFtumor necrosis factor;WCCwhite cell count